Cargando…
Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report
BACKGROUND: Pancreatic cancer has a poor prognosis, and it is traditionally treated with chemotherapy. Fortunately, immunotherapy has rapidly changed the landscape of solid tumor treatment, and improving the survival of cancer patients. However, pancreatic cancer is non-immunogenic, and single agent...
Autores principales: | Ye, Yanghui, Zheng, Song |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645965/ https://www.ncbi.nlm.nih.gov/pubmed/34880877 http://dx.doi.org/10.3389/fimmu.2021.785400 |
Ejemplares similares
-
Germline mutation of TSC1 or TSC2 gene in Chinese patients with bilateral renal angiomyolipomas and mutation spectrum of Chinese TSC patients
por: Jiangyi, Wang, et al.
Publicado: (2020) -
Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing
por: Tyburczy, Magdalena E., et al.
Publicado: (2015) -
Mutations in ALK and TSC1 in a gastrointestinal stromal tumor: a case report
por: Song, Qingzhi, et al.
Publicado: (2021) -
Case Report: Successful Immunotherapy Improved the Prognosis of the Unfavorable Subset of Cancer of Unknown Primary
por: Mei, Jie, et al.
Publicado: (2022) -
Epigenetic Modulation of Class-Switch DNA Recombination to IgA by miR-146a Through Downregulation of Smad2, Smad3 and Smad4
por: Casali, Paolo, et al.
Publicado: (2021)